Article
Oncology
Priyanka Sharma, Vandana G. Abramson, Anne O'Dea, Lauren Nye, Ingrid Mayer, Harsh B. Pathak, Marc Hoffmann, Shane R. Stecklein, Manana Elia, Sharon Lewis, Jecinta Scott, Jilliann A. De Jong, Yen Y. Wang, Rachel Yoder, Kelsey Schwensen, Karissa Finke, Jaimie Heldstab, Stephanie LaFaver, Stephen K. Williamson, Milind A. Phadnis, Gregory A. Reed, Bruce F. Kimler, Qamar J. Khan, Andrew K. Godwin
Summary: The combination of alpelisib and nab-paclitaxel showed good tolerability and promising efficacy in patients with HER2-negative metastatic breast cancer, especially in those with PIK3CA-mutated tumor/ctDNA. The impact of metabolic status on treatment response warrants further investigation.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Yizhao Xie, Chengcheng Gong, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Ting Li, Yannan Zhao, Yi Li, Shihui Hu, Biyun Wang, Xichun Hu
Summary: This phase II trial demonstrated satisfactory efficacy and safety of nab-paclitaxel in metastatic breast cancer patients with visceral metastases, with better treatment outcome for patients in first line therapy. Further alternatives may be required for patients with premenopausal status or brain metastasis. The study also showed the efficacy and safety of 125 mg/m2 nab-paclitaxel among Asian patients.
Article
Multidisciplinary Sciences
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van't Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Summary: HER2-targeted therapy significantly improves outcomes in early breast cancer patients. Two HER2-targeted combinations have shown promising efficacy in early breast cancer patients at high risk of recurrence, potentially aiding in identifying patients who can safely reduce cytotoxic chemotherapy without compromising outcomes.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Carmen Criscitiello, Antonio Marra, Stefania Morganti, Paola Zagami, Sara Gandini, Angela Esposito, Giuseppe Curigliano
Summary: This study retrospectively analyzed the clinical characteristics and outcomes of patients with metastatic breast cancer treated with targeted therapy, immunotherapy, and combination therapy from 2014 to 2019 at a medical institution. The results showed that patients with triple negative breast cancer had poorer outcomes, and targeted therapy was associated with improved response rates and progression-free survival. Patients with fewer metastatic sites and baseline lactate dehydrogenase below the upper limit of normal had better overall survival.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Multidisciplinary Sciences
Hazem Ghebeh, Adher Al-Sayed, Riham Eiada, Leilani Cabangon, Dahish Ajarim, Kausar Suleman, Asma Tulbah, Taher Al-Tweigeri
Summary: The combination therapy of Durvalumab and Paclitaxel is safe and effective in metastatic TNBC, with common adverse events including headache, peripheral neuropathy, fatigue, and skin rash. The confirmed objective response rate was observed in five patients, with a median duration of 10.0 months, and the median progression-free survival and overall survival were 5 and 20.7 months, respectively.
SCIENTIFIC REPORTS
(2021)
Article
Chemistry, Multidisciplinary
Xinyun Qiu, Yan Qu, Beibei Guo, Huan Zheng, Fenghua Meng, Zhiyuan Zhong
Summary: ATN-MPTX, constructed with the clinically validated ATN peptide as a ligand and reduction-sensitive biodegradable micelles as a vehicle, demonstrates strong and selective induction of ICD and chemo-immunotherapy for TNBC, showing superior tumor accumulation and treatment efficacy compared to controls in therapeutic studies.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This trial evaluated the safety and efficacy of ipatasertib in combination with different chemotherapy regimens for metastatic triple-negative breast cancer (mTNBC). The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and the overall response rates and progression-free survival varied among the different treatment arms. Further study is needed to better understand the role of AKT inhibition in the treatment of TNBCs.
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This study evaluated the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic triple-negative breast cancer (mTNBC). The primary endpoints were safety and recommended phase II dose (RP2D), while secondary endpoints included progression-free survival (PFS), response rate, and overall survival. The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and further research is needed to understand the role of AKT inhibition in the treatment of TNBC.
Article
Oncology
Esther N. Pijnappel, Nienke P. M. Wassenaar, Oliver J. Gurney-Champion, Remy Klaassen, Koen van der Lee, Marjolein C. H. Pleunis-van Empel, Dick J. Richel, Marie C. Legdeur, Aart J. Nederveen, Hanneke W. M. van Laarhoven, Johanna W. Wilmink
Summary: The combination of LDE225 with gemcitabine and nab-paclitaxel was well-tolerated and effective in patients with metastatic PDAC, especially in those with poor baseline tumor perfusion. These results suggest a potential clinical benefit of this combination therapy in patients who have received prior FOLFIRINOX treatment.
Article
Oncology
L. Cortesi, M. Venturelli, G. Cortesi, F. Caggia, A. Toss, E. Barbieri, U. De Giorgi, V. Guarneri, A. Musolino, E. De Matteis, A. Zambelli, G. Bisagni, M. Dominici
Summary: In this clinical trial, the efficacy and safety of pembrolizumab plus carboplatin in treating first-line visceral disease BRCA-related luminal breast cancer were investigated. The primary aim of achieving an overall response rate >70% was not met, but further investigation is needed.
Article
Medicine, General & Internal
A. Bardia, S. A. Hurvitz, S. M. Tolaney, D. Loirat, K. Punie, M. Oliveira, A. Brufsky, S. D. Sardesai, K. Kalinsky, A. B. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortes, J. O'Shaughnessy, V Dieras, C. Ferrario, P. Schmid, L. A. Carey, L. Gianni, M. J. Piccart, S. Loibl, D. M. Goldenberg, Q. Hong, M. S. Olivo, L. M. Itri, H. S. Rugo
Summary: Patients with metastatic triple-negative breast cancer treated with Sacituzumab govitecan had significantly longer progression-free and overall survival compared to standard chemotherapy, but experienced more frequent myelosuppression and diarrhea as adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Oncology
A. Gombos, A. Goncalves, G. Curigliano, R. Bartsch, J. A. Kyte, M. Ignatiadis, A. Awada
Summary: Estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancer is the most common subtype, accounting for around 70% of cases. Endocrine therapy (ET) combined with cyclin-dependent kinases (CDK) 4/6 inhibitors is the standard treatment for advanced luminal breast cancer. This review paper discusses the challenges of endocrine resistance mechanisms, the development of novel ET options, and the improvement of post-endocrine therapeutic approaches in ER+/HER2- metastatic breast cancer.
Article
Oncology
Filipa Lynce, James T. Williams, Meredith M. Regan, Craig A. Bunnell, Rachel A. Freedman, Sara M. Tolaney, Wendy Y. Chen, Erica L. Mayer, Ann H. Partridge, Eric P. Winer, Beth Overmoyer
Summary: Preclinical studies suggest JAK2-STAT3 pathway is important in breast cancer stem cells. Ruxolitinib is a JAK1/2 inhibitor. This study aimed to find the recommended dose of ruxolitinib in combination with paclitaxel for HER2-negative metastatic breast cancer patients. The combination showed good tolerability and clinical activity.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2021)
Article
Oncology
Cecilia Monge, Changqing Xie, Yuta Myojin, Kelley Coffman, Donna Mabry Hrones, Sophie Wang, Jonathan M. Hernandez, Bradford J. Wood, Elliot B. Levy, Israa Juburi, Stephen M. Hewitt, David E. Kleiner, Seth M. Steinberg, William D. Figg, Bernadette Redd, Philip Homan, Maggie Cam, Benjamin Ruf, Austin G. Duffy, Tim F. Greten
Summary: This study evaluated the safety and efficacy of the combination of PexaVec, durvalumab, and tremelimumab in patients with refractory pMMR mCRC. The results showed that the combination therapy has potential clinical activity without unexpected toxicities.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Yaxin Liu, Guohong Song, Lijun Di, Hanfang Jiang, Ran Ran, Ruyan Zhang, Yan Zhang, Huiping Li
Summary: This study compared the efficacy and safety of a 3-week versus 4-week schedule of nab-paclitaxel in patients with metastatic breast cancer, and found that the 3-week schedule had a longer progression-free survival and a lower rate of toxicity-related treatment discontinuation and dose delays compared to the 4-week schedule.